The present application relates to the technical field of biomedicine, and specifically discloses a multi-target kinase inhibitor and a pharmaceutical composition comprising the multi-target kinase inhibitor, and further discloses a preparation method and a use of the multi-target kinase inhibitor. The multi-target kinase inhibitor provided by the present application has a general structural formula as shown by formula (I), wherein the structure of R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit enzymatic activity of RET, VEGFR3 and PDGFRA, and can effectively treat diseases regulated by a multi-target kinase and associated with an abnormality of a signal transduction pathway of the multi-target kinase, including cancers in the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eyes, liver, skin, head and/or neck and distal metastatic carcinomas thereof, as well as lymphoma, sarcoma, and leukemia, etc. The pharmaceutical composition of the present application comprises the multi-target kinase inhibitor as an active component, which accounts for 1% to 50% by weight of the composition.La présente invention se rapporte au domaine technique de la biomédecine, et concerne en particulier un inhibiteur de kinase multi-cibles et une composition pharmaceutique comprenant l'inhibiteur de kinase multi-cibles, et concerne en outre un procédé de préparation et une utilisation de l'inhibiteur de kinase multi-cibles. L'inhibiteur de kinase multi-cibles fourni par la présente invention a une formule structurale générale telle que représentée par la formule (I), la structure de R étant choisie parmi la formule (a), la formule (b), la formule (c), la formule (d), la formule (e) et la formule (f). L'inhibiteur de kinase multi-cibles peut inhiber de manière efficace l'activité enzymatique de RET, VEGFR3 et PDGFRA, et peut traiter de manière e
